Education
About Us
Working with TipRanks
Follow Us
Diamedica Therapeutics Inc (DMAC)
NASDAQ:DMAC
Earnings Data
Report Date
Aug 06, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.19Last Year’s EPS
-0.13Same Quarter Last Year
Strong Buy
Based on 3 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 13, 2025
|% Change Since: -8.29%
|Next Earnings Date:Aug 06, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a positive outlook with significant progress in clinical programs and financial stability, despite some increased operational expenses.Company Guidance
During DiaMedica Therapeutics' First Quarter 2025 Conference Call, the company provided guidance on their preeclampsia and stroke programs. They are nearing completion of Part 1a of their Phase 2 preeclampsia trial, focusing on safety, blood pressure reduction, and uterine blood flow metrics, with preliminary results expected between late June and early July. The stroke program has reached 20-25% enrollment for interim analysis, with results targeted for the first half of 2026. Financially, DiaMedica reported $37.3 million in cash and investments at the end of March 2025, with a net cash usage of $7.1 million in Q1, and anticipates that current funds will last into Q3 of 2026.Progress in Preeclampsia Program
DiaMedica is close to identifying a target dose for its Phase 2 preeclampsia trial, with preliminary top-line results expected between late June and early July.
Steady Enrollment in Stroke Program
Participant enrollment in the stroke program is progressing, with enrollment between the 20th and 25th percentile for interim analysis.
Financial Stability
DiaMedica reported a total combined cash and investments of $37.3 million as of March 31, 2025, providing a runway into Q3 of 2026.
Increased R&D Investment
Research and development expenses increased to $5.7 million for Q1 2025, primarily due to the continuation of the ReMEDy2 clinical trial and global expansion.
DMAC Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DMAC Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 13, 2025 | $3.98 | $4.00 | +0.50% |
Mar 17, 2025 | $5.99 | $5.21 | -13.02% |
Nov 13, 2024 | $4.26 | $4.12 | -3.29% |
Aug 07, 2024 | $3.25 | $3.35 | +3.08% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Diamedica Therapeutics Inc (DMAC) report earnings?
Diamedica Therapeutics Inc (DMAC) is schdueled to report earning on Aug 06, 2025, TBA Not Confirmed.
What is Diamedica Therapeutics Inc (DMAC) earnings time?
Diamedica Therapeutics Inc (DMAC) earnings time is at Aug 06, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DMAC EPS forecast?
DMAC EPS forecast for the fiscal quarter 2025 (Q2) is -0.19.